Here are the DEF 14A proxy statements from Reviva Pharma Holdings Inc (RVPH) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow RVPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVPH filings page.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) will hold its virtual annual meeting on December 18, 2026. Stockholders will vote on five director nominees, auditor ratification, advisory executive compensation, adjournment, and an amendment that would authorize a reverse split at a ratio from 1-for-2 to 1-for-100 at any time before December 31, 2027. The Board would decide whether to implement the split and select the ratio, without further stockholder approval. The Board recommends voting “FOR” each proposal.
As of October 30, 2026, 13,110,377 common shares were outstanding. The 2025 pay-versus-performance table reports a net loss of $19,864,902, compared with $29,918,802 in 2024. The 2025 summary compensation table lists total compensation of $1,442,121 for CEO Laxminarayan Bhat and $659,670 for CFO Narayan Prabhu.
Reviva Pharmaceuticals Holdings (RVPH) called its 2025 annual meeting for December 18, 2025 at 11:00 a.m. Pacific Time, to be held virtually. Stockholders will vote on electing five directors, ratifying Baker Tilly US, LLP as auditor for 2025, an advisory say‑on‑pay, and two capital-structure items.
The Board seeks approval to increase authorized common shares from 315,000,000 to 515,000,000 and to authorize a reverse stock split of issued common shares at a ratio between 1:2 and 1:20, at any time prior to December 31, 2026, at the Board’s discretion and without further stockholder approval. An adjournment proposal is included if additional solicitation is needed. The Board recommends voting “FOR” all proposals.
Holders of record as of October 21, 2025 may vote; 114,078,619 shares of common stock were outstanding on the record date. Voting can be completed online, by phone, by mail, or during the virtual meeting using a 16‑digit control number.